Introduction {#S0001}
============

Over the past decades, *Acinetobacter baumannii* has become a common causative agent of multidrug-resistant, hospital-acquired infections worldwide. In addition, it has been shown to be an important cause of community-acquired infection.[@CIT0001],[@CIT0002] Unlike hospital-acquired *A. baumannii*, community-acquired pneumonia caused by *A. baumannii* is characterized by a fulminant course and high mortality rates.[@CIT0003] Carbapenem-resistant *A. baumannii* is a major threat for public health. In 2017, the World Health Organization classified this pathogen as the top priority for the development of additional antibiotics.[@CIT0004] The most important mechanism of carbapenem resistance in *A. baumannii* is associated with the production of carbapenem-hydrolyzing class D OXA-type β-lactamases. Of note, five groups of OXA-type carbapenemases (ie, OXA-23-, OXA-24/40-, OXA-51-, OXA-58-, and OXA-143-like) are frequently encountered.[@CIT0005] The gene *bla*~OXA-72~ -- one of the most important allelic variants within the *bla*~OXA-24/40~ group -- was initially identified in an *A. baumannii* strain isolated in 2004 in Thailand (GenBank accession no. AY739646). Subsequently, *bla*~OXA-72~-carrying *A. baumannii* strains from human and animal origins have been widely identified. However, thus far, few *bla*~OXA-72~-positive *A. baumannii* strains have been reported in China and the genetic context of *bla*~OXA-72~ is largely unknown.[@CIT0006] In the present study, we reported the first identification of a carbapenem-resistant *A. baumannii* isolate associated with fulminant community-acquired pneumonia. This isolate belonged to a rare sporadic clone, harboring both the *bla*~OXA-72~ and the intrinsic *bla*~OXA-259~ genes. Whole-genome sequencing and microbiological analysis were performed to elucidate its mechanism of resistance to carbapenems.

Materials and methods {#S0002}
=====================

A 66-year-old male patient was hospitalized with symptoms indicative of community-acquired pneumonia (CAP), septic shock, respiratory failure, and fever. *A. baumannii* isolate A52 was cultured from the sputum sample of the patient within 24 hrs after admission. This patient resided in the countryside, without a history of recent travel or hospitalization. The presence of CAP was considered if pneumonia was not acquired in a hospital, and the interval between the onset of symptoms and previous discharge from hospital was \>30 days. Community-associated *A. baumannii* was defined as isolates cultured from sputum and/or a blood specimen obtained from CAP patients and collected within 48 hrs after admission.[@CIT0003],[@CIT0007] The quality of the sputum specimen for culture was determined through microscopy. The patient was successfully treated with a one-week administration of imipenem and linked to a good prognosis. The initial identification of species was performed using Vitek 2 (bioMérieux, Marcy-l'Étoile, France) and Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Corp., Billerica, MA, USA). *A. baumannii* A52 was subjected to antimicrobial susceptibility testing by the microdilution broth method for the following antimicrobial agents: amikacin, ceftazidime, cefotaxime, cefepime, ciprofloxacin, colistin, gentamicin, imipenem, meropenem, minocycline, piperacillin, and tigecycline, which were purchased from Sigma-Aldrich (St. Louis, MO, USA). The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) 2018 guidelines, except for tigecycline.[@CIT0008] Although officially there are no clinical breakpoints for tigecycline against *A. baumannii* given by either CLSI or European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, the US FDA breakpoints (MIC ≤2 mg/L for susceptibility and MIC ≥8 mg/L for resistance) or EUCAST breakpoints version 8.0 (MIC ≤1 mg/L for susceptibility and MIC \>2 mg/L for resistance) for Enterobacteriaceae are commonly applied (<http://www.eucast.org/clinical_breakpoints>). *Escherichia coli* (ATCC 25922) and *Pseudomonas aeruginosa* (ATCC 27853) were used as quality control strains for both species identification and antimicrobial susceptibility testing.

Whole-genome sequencing (WGS) of *A. baumannii* A52 was performed using both the HiSeq X10 (Illumina, San Diego, CA, USA), with the 150 bp paired-end protocol, and the MinION (Nanopore, Oxford, UK) platforms. Hybrid assembly of both short Illumina reads and long Nanopore reads was constructed using Unicycler v 0.4.7 with the Pilon v1.23 option on for the modification of the assembled reads.[@CIT0009] The genome annotation was performed using NCBI Prokaryotic Genome Annotation Pipeline. Antibiotic resistance genes was queried using the ResFinder database at the Center for Genomic Epidemiology (<http://www.genomicepidemiology.org/>).[@CIT0010] *In silico* multilocus sequence typing (MLST) analysis and bacterial source tracking for implementing both single-nucleotide polymorphism (SNP) and core genome multilocus sequence typing (cgMLST) strategies were performed by our recently updated BacWGSTdb server.[@CIT0011] Easyfig was used to analyze the genetic surroundings of antimicrobial resistance genes.[@CIT0012] The nucleotide sequence of the chromosome and plasmids of *A. baumannii* isolate A52 have been deposited in NCBI GenBank under accession numbers CP034092-CP034097. The sputum sample and clinical isolate of *A. baumannii* isolate A52 were generated as part of routine hospital laboratory procedures. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China. Written informed consent was obtained from the patient, which included the publication of the case details.

Results and discussion {#S0003}
======================

Antimicrobial susceptibility testing showed that *A. baumannii* A52 was resistant to meropenem. However, it remained susceptible to several other antimicrobial agents, including imipenem ([Table S1](#ST0001)). In particular, for the broth microdilution method, the minimum inhibitory concentrations of meropenem and imipenem were 8 mg/L and 2 mg/L, respectively. In addition to carbapenemases, the permeability defects, such as overexpression of efflux system, may also contribute to carbapenem resistance in *A. baumannii*. The sequences of efflux pump regulatory genes were analyzed, which are known to be involved in antibiotic resistance, namely, the AdeR/S two-component system and AdeN and AdeB, which regulate the AdeIJK and AdeAB efflux pumps, respectively. The regulatory efflux pumps AdeR and AdeS of *A. baumannii* A52 showed 99% (1 substitution) and 100% amino acid sequence identities, respectively, with those of *A. baumannii* ATCC 17978, whereas AdeN and AdeB of *A. baumannii* A52 showed 100% amino acid sequence identities with those of *A. baumannii* ATCC 17978. These findings highlight the efflux pump regulatory genes in this strain may have a negative influence in resistance to carbapenems. WGS to assess the sequence type (ST) identified *A. baumannii* A52 as ST880 and ST77, according to the Oxford and Pasteur MLST schemes, respectively. It contained three genes (*bla*~OXA-72~, *bla*~OXA-259~, and *bla*~ADC-26~) conferring resistance to β-lactams, which were not preceded by an insertion element. This finding was consistent with the phenotypic data. In addition, we found that this strain lacked the *A. baumannii* antibiotic resistance island, which confers resistance to multiple antibiotics (eg, aminoglycosides, beta-lactams, sulfonamides, and tetracyclines). The absence of an antibiotic resistance island in *A. baumannii* may explain the high susceptibility of the community-acquired strain to antibiotics.

The *bla*~OXA-72~ gene was located on the 8,493-bp plasmid pA52-OXA-72. The backbone of the pA52-OXA-72 plasmid is almost identical to that of pAbIHIT32296 -- a *bla*~OXA-72~-carrying plasmid in *A. baumannii* recovered from a captive grey parrot in Germany. The shared sequence of these plasmids contains the *bla*~OXA-72~ gene. However, in pA52-OXA-72, this gene is in a different location and orientation. Furthermore, the plasmid pA52-OXA-72 exhibited only partial similarity to other OXA-72-encoding plasmids (size range: 8,771--12,056 bp) in various *Acinetobacter* spp. recovered from patients in different countries ([Figure 1](#F0001){ref-type="fig"}, [Table S2](#ST0002)). Plasmid pA52-OXA-72 contained 11 open reading frames and encoded a replication protein belonging to the replication protein 3 superfamily1.[@CIT0013] In addition, it carried genes encoding a putative type II toxin--antitoxin system (VapC2-VapB2). These genes were also present in other OXA-72-encoding plasmids (eg, pIEC338SCOX) and may be involved in plasmid maintenance ([Figure 2](#F0002){ref-type="fig"}).[@CIT0014] The *bla*~OXA-72~ gene was flanked by XerC/XerD recombination sites, which were identical to those of previously reported plasmids. This finding indicated the importance of mobilization through the site-specific recombination mechanism. As previously suggested, the XerC/XerD-sites may be involved in a site-specific recombination system responsible for the mobilization of the *bla*~OXA-72~ gene among *Acinetobacter* spp. Moreover, a conserved region (ie, *ydaF2-vapB2-vapC2-orf1*) in pA52-OXA-72 also bracketed with the XerC/XerD-sites and showed high sequence identity to the regions in plasmid pIEC338SCOX. This observation suggests that different plasmids may exchange carbapenem-hydrolyzing class D OXA-type β-lactamases genes and other components within a restricted region between the two closest XerC/XerD binding sites.Figure 1Comparison of the homologous regions shared by pA52-OXA-72, pAbIHIT32296, and pIEC338SCOX. Open arrows represent coding sequences (red arrows, *bla*~OXA-72~) and indicate the direction of transcription. The arrow size is proportional to the gene length. *repA*, replicase gene; *traB*, gene coding bacterial conjugation TrbI-like family protein; *ydaF2*, gene encoding putative ribosomal N-acetyltransferase; *vapB2*, gene encoding putative antitoxin; *vapC2*, gene encoding putative ribonuclease/toxin; *parA*, gene coding plasmid partition protein A; XerC/XerD, specific site of the tyrosine recombinases XerC and XerD (indicated by asterisks).Figure 2Plasmid sequence alignment of *bla*~OXA-72~-carrying plasmids that revealed partial sequence identity to pA52-OXA-72.

The origin of *A. baumannii* A52 remains unknown. We analyzed the phylogenetic relationship between *A. baumannii* A52 and a total of 3,417 *A. baumannii* strains currently deposited in the NCBI GenBank database. This analysis was performed using the following two bacterial source tracking strategies: SNP and cgMLST. Both strategies suggested that *A. baumannii* A52 belongs to a rare sporadic clone. Notably, the closest relative was an ST1325 (single-locus variant of ST880) isolate known as HC9436, which was recovered from the endobronchial intubation tube of a patient in Honduras in 2015 ([Table S3](#ST0003), [Figure S1](#SF0001)). However, the present patient had no history of recent overseas travel or direct contact with foreigners. Hence, there was no epidemiological link identified between this Chinese patient and the previously reported case. *A. baumannii* CAP exhibits seasonal variation, with a higher incidence reported in the warmer and more humid months of the year.[@CIT0003] Consistent with previously reported cases, the present patient was admitted in August (ie, the hot and rainy season in China).[@CIT0015]--[@CIT0017]Figure S1Phylogenetic relationship between *A. baumannii* A52 and the closely related *A. baumannii* strains currently deposited in the NCBI GenBank database. The lines connecting the circles indicate the clonal relationship between different isolates and the digital numbers on the lines illustrate the number of allelic differences.

The OXA-72-producing *A. baumannii* isolates have been mainly obtained from hospitals and other reservoirs (ie, livestock/companion animals, and environment) in South America, Southern Asia, and Eastern Europe.[@CIT0018]--[@CIT0020] More recently, a cross-sectional study reported a high prevalence and clonal dissemination of OXA-72-producing *A. baumannii* in a Chinese hospital, corresponding to the predominant international clone 2. However, noninternational clone 2 *A. baumannii* strains (ie, ST78 in Germany, ST1 in Serbia, and ST79 in Brazil) carrying *bla*~OXA-72~ have also been reported.[@CIT0020]--[@CIT0022] Therefore, based on the genetic flexibility mediated by the elements for site-specific recombination, the *bla*~OXA-72~-carrying plasmids of *A. baumannii* may represent powerful vehicles for the acquisition, horizontal-transfer, and evolution of carbapenem resistance.

Conclusion {#S0004}
==========

We reported the identification of a carbapenem-resistant community-acquired *A. baumannii* isolate in China. This isolate belongs to a rare sporadic clone harboring a unique *bla*~OXA-72~-carrying plasmid. Our study highlights the transmission potential of OXA-72-producing *A. baumannii* in the community. Continuous surveillance is necessary to monitor the transmission dynamics of the *bla*~OXA-72~ gene in the community.
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*A. baumannii, Acinetobacter baumannii*; CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; WGS, whole-genome sequencing; MLST, multilocus sequence typing; ST, sequence type; cgMLST, core genome multilocus sequence typing; SNP, single nucleotide polymorphism.
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Table S1Antibiotic resistance profile of *A. baumannii* isolate A52AntimicrobialMIC (mg/L)Interpretationamikacin0.5Scefepime4Scefotaxime8Sceftazidime4Sciprofloxacin0.125Scolistin0.125Sgentamicin1Simipenem2Smeropenem8Rminocycline0.5Spiperacillin16Stigecycline\*0.5S[^1] Table S2Characterisation of *Acinetobacter* spp. plasmids containing *bla*~OXA-72~ gene recovered from different countriesPlasmidsLength (bp)HostCollection YearIsolation sourceCountryAccession numberReferencespA52-OXA-728,493Human2015SputumChinaCP034097.1This studypAbIHIT322968,493Grey parrot2016NoseGermanyKY704308.1[@CIT0023]pIEC338SCOX10,498Human2014Tracheal secretionBrazilCP015146.1[@CIT0024]pAP10253-110,498Human2012-BrazilKY499579.1[@CIT0024]pAB-ML12,056Human2012-TaiwanKT022421.1[@CIT0025]pMMCU1\*8,771Human-BloodSpainGQ342610.1[@CIT0026]pAB-NCGM2538,970Human2012-JapanAB823544.1[@CIT0027]pAB12010,879Human2010Respiratory tractLithuaniaJX069966.1[@CIT0028]pABVA01\*8,963Human2000Bronchoalveolar lavage fluidItalyFM210331.1[@CIT0029]pMAL-19,810Human-UrineSerbiaKX230793.1[@CIT0030]pMMA2\*10,679Human-BloodSpainGQ377752.1[@CIT0026][^2] Table S3Information of closely related strains to *A. baumannii* A52IsolateAccession numberSTHostDiseaseIsolation SourceCountry StateCollection YearDifferent allelesHC9436NQXM011325Homo sapiensAcinetobacter infectionEndobronchial tubeHonduras: Cortes, San Pedro Sula2015-09-15187XH198MDWM01112\-\--China: Hangzhou2014-03596ATCC_17978CP018664112Homo sapiensNosocomial infectionBlood\--608ATCC_17978-mffCP012004112Homo sapiensMeningitis-Canada2014608AB042CP019034112Homo sapiensNosocomial infectionLab mutation of ATCC 17978\--610XH181MDWH01112\-\--China: Hangzhou2014-03610XH182MDWJ01112\-\--China: Hangzhou2014-03610XH184MDWL01112\-\--China: Hangzhou2014-03613XH192MDWI01112\-\--China: Hangzhou2014-03613XH183MDWK01112\-\--China: Hangzhou2014-03614XH193MDWF01112\-\--China: Hangzhou2014-03614XH191MDWG01112\-\--China: Hangzhou2014-03615ATCC_17978CP000521112\-\-\-\--763NIPH_70APRC01296Homo sapiens-Tracheal secretionCzech Republic: Praha19921229XH639LYKQ011342Homo sapiens-SputumChina: Hangzhou2014-08-291340
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[^1]: **Notes:** Antimicrobial susceptibilities, reported as MIC (mg/L), were interpreted in accordance with established breakpoints: amikacin (S≤16, I=32, R≥64), cefepime (S≤8, I=16, R≥32), cefotaxime (S≤8, I=16-32, R≥64), ceftazidime (S≤8, I=16, R≥32), ciprofloxacin (S≤1, I=2, R≥4), colistin (S≤2, R≥4), gentamicin (S≤4, I=8, R≥16), imipenem (S≤2, I=4, R≥8), meropenem (S≤2, I=4, R≥8), minocycline (S≤4, I=8, R≥16), piperacillin (S≤16, I=32-64, R≥128), tigecycline-FDA (S≤2, I=4, R≥8), tigecycline-EUCAST (S≤1, I=2, R\>2). \*The EUCAST breakpoints for Enterobacteriaceae are applied to interpret the MIC of tigecycline against *A. baumannii*.

[^2]: **Notes:** \*These plasmids contain *bla*~OXA-24~, a single-nucleotide variant of *bla*~OXA-72~.
